NasdaqCM:IMTXBiotechs
Is Immatics (IMTX) Building a PRAME-Focused Platform or Stretching Its Oncology Ambitions Too Thin?
In early 2026, Immatics highlighted past progress across its PRAME franchise and outlined multiple upcoming milestones, including advancing its PRAME cell therapy anzu-cel toward potential approval and generating further data from its second-generation candidate IMA203CD8 in gynecologic cancers.
An intriguing element of the update is Immatics’ plan to combine its TCR bispecifics IMA402 and IMA401 in lung cancer, signaling a broader effort to position PRAME-targeted therapies across several...